MorphoSys AG
OTC: MPSYF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Arkadius Pichota
- Employees
- 524
- Headquarters
- Planegg, Germany
- IPO year
- 2010
- Market cap
- $2.8B
- Website
- https://www.morphosys.com
Loading MPSYF…
Loading profile data…Frequently asked questions about MPSYF
What does MorphoSys AG (MPSYF) do?
MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, incl...
Where does MPSYF trade?
MorphoSys AG (MPSYF) trades on the Other OTC.
What sector is MPSYF in?
MorphoSys AG (MPSYF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MorphoSys AG?
Arkadius Pichota is the chief executive officer of MorphoSys AG (MPSYF).
Where is MorphoSys AG headquartered?
MorphoSys AG is headquartered in Germany.
Does MPSYF pay a dividend?
MorphoSys AG (MPSYF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MPSYF go public?
MorphoSys AG (MPSYF) completed its initial public offering in 2010.